Results 171 to 180 of about 54,075 (219)

Trastuzumab

BioDrugs, 1999
Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185(HER2) (HER2) which is overexpressed in 25 to 30% of breast cancer tumours. The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo.
C M, Perry, L R, Wiseman
openaire   +2 more sources

Trastuzumab

Reactions Weekly, 2019
  +9 more sources

Trastuzumab

Reactions Weekly, 2009
Edith A, Perez, Frances M, Palmieri, Shelly M, Brock   +2 more
openaire   +3 more sources

Trastuzumab/trastuzumab emtansine

Reactions Weekly, 2023
openaire   +1 more source

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti   +2 more
exaly  

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Lancet, The, 2023
Wei-Pang Chung, Seock-Ah Im, Vinod Ganju
exaly  

Anastrozole/trastuzumab/trastuzumab emtansine

Reactions Weekly, 2022
openaire   +1 more source

Pertuzumab/trastuzumab/trastuzumab emtansine

Reactions Weekly, 2021
openaire   +1 more source

Trastuzumab-emtansine/trastuzumab

Reactions Weekly, 2020
openaire   +1 more source

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2023
Fabrice Andre, Yeon Hee Park, Martina Uttenreuther-Fischer   +2 more
exaly